Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Продленная адъювантная терапия анастрозолом у больных раком молочной железы в период постменопаузы: результаты рандомизированного исследования 6а Австрийской группы по изучению рака молочной железы и колоректального рака
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Raimund Jakesz, Richard Greil, Michael Gnant, Marianne Schmid, Werner Kwasny, Ernst Kubista, Brigitte Mlineritsch, Christoph Tausch, Michael Stierer, Friedrich Hofbauer, Karl Renner, Christian Dadak, Ernst Recklinger, Hellmut Samonigg от имени группы по изучению рака молочной железы и колоректального рака
Полный текст
Список литературы
1. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687–717.
2. Chia S, Bryce C, Gelmon K. The 2000 EBCTCG overview: a wideninggap. Lancet 2005; 365: 1665–6.
3. Fisher B, Dignam J, Bryant J et al. Five versus more than fi ve years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996; 88: 1529–42.
4. Peto R. Five years of tamoxifen – or more? J Natl Cancer Inst 1996; 88: 1791–3.
5. Stewart HJ, Prescott RJ, Forrest AP. Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years. J Natl Cancer Inst 2001; 93: 456–62.
6. Tormey DC, Gray R, Falkson HC. Postchemotherapy adjuvant tamoxifen therapy beyond fi ve years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group. J Natl Cancer Inst 1996; 88: 1828–33.
7. ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365: 60–2.
8. Boccardo F, Rubagotti A, Puntoni M et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole trial. J Clin Oncol 2005; 23: 5138–47.
9. Jakesz R, Jonat W, Gnant M et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 366: 455–62.
10. Jonat W, Gnant M, Boccardo F et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol 2006; 7: 991–6.
11. Jakesz R, Gnant M, Greil R et al. The benefi ts of sequencing adjuvant tamoxifen and anastrozole in postmenopausal women with hormone-responsive early breast cancer: 5-yearanalysis of ABCSG Trial 8. Breast Cancer Res Treat 2005; 94 (Suppl. 1): S10.
12. Goss PE, Ingle JN, Martino S et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated fi ndings from NCIC CTG MA.17. J Natl Cancer Inst 2005; 97: 1262–71.
13. Schmid M, Jakesz R, Samonigg H et al. Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian Breast and Colorectal Cancer Study Group trial 6. J Clin Oncol 2003; 21: 984–90.
14. Sobin LH, Wittekind C. TNM classifi cation of malignant tumours. 5th ed. New York: Wiley; 1997.
15. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975; 31: 103–15.
16. Cox DR. Regression models and life tables. J R Stat Soc 1972; 34: 187–220.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations . J Am Stat Assoc 1958; 53: 457–81.
18. Dowsett M, Smith I, Skene A et al. Biological and clinical outcomes from a phase II placebo-controlled neoadjuvant study of anastrozole alone or with gefi tinib in postmenopausal women with ER/PgR+ breast cancer (Study 223). J Clin Oncol 2006; 24: 6s.
19. Viale G, Regan M, Dell'Orto B et al. Central review of ER, PgR and HER2 in BIG 1-98 evaluating letrozole vs tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Breast Cancer Res Treat 2005; 94: S13.
20. Dowsett M, Martin LA, Smith I, Johnston S. Mechanisms of resistance to aromatase inhibitors. J Steroid Biochem Mol Biol 2005; 95: 167–72.
21. Bertelli G, Garrone O, Merlano M et al. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer. Oncology 2005; 69: 471–7.
22. Seeman E. Pathogenesis of bone fragility in women and men. Lancet 2002; 359: 1841–50. jnci.oxfordjournals.org JNCI | Articles 1853
23. Winer EP, Hudis C, Burstein HJ et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor – positive breast cancer: status report 2004. J Clin Oncol 2005; 23: 619–29.
2. Chia S, Bryce C, Gelmon K. The 2000 EBCTCG overview: a wideninggap. Lancet 2005; 365: 1665–6.
3. Fisher B, Dignam J, Bryant J et al. Five versus more than fi ve years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996; 88: 1529–42.
4. Peto R. Five years of tamoxifen – or more? J Natl Cancer Inst 1996; 88: 1791–3.
5. Stewart HJ, Prescott RJ, Forrest AP. Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years. J Natl Cancer Inst 2001; 93: 456–62.
6. Tormey DC, Gray R, Falkson HC. Postchemotherapy adjuvant tamoxifen therapy beyond fi ve years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group. J Natl Cancer Inst 1996; 88: 1828–33.
7. ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365: 60–2.
8. Boccardo F, Rubagotti A, Puntoni M et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole trial. J Clin Oncol 2005; 23: 5138–47.
9. Jakesz R, Jonat W, Gnant M et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 366: 455–62.
10. Jonat W, Gnant M, Boccardo F et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol 2006; 7: 991–6.
11. Jakesz R, Gnant M, Greil R et al. The benefi ts of sequencing adjuvant tamoxifen and anastrozole in postmenopausal women with hormone-responsive early breast cancer: 5-yearanalysis of ABCSG Trial 8. Breast Cancer Res Treat 2005; 94 (Suppl. 1): S10.
12. Goss PE, Ingle JN, Martino S et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated fi ndings from NCIC CTG MA.17. J Natl Cancer Inst 2005; 97: 1262–71.
13. Schmid M, Jakesz R, Samonigg H et al. Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian Breast and Colorectal Cancer Study Group trial 6. J Clin Oncol 2003; 21: 984–90.
14. Sobin LH, Wittekind C. TNM classifi cation of malignant tumours. 5th ed. New York: Wiley; 1997.
15. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975; 31: 103–15.
16. Cox DR. Regression models and life tables. J R Stat Soc 1972; 34: 187–220.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations . J Am Stat Assoc 1958; 53: 457–81.
18. Dowsett M, Smith I, Skene A et al. Biological and clinical outcomes from a phase II placebo-controlled neoadjuvant study of anastrozole alone or with gefi tinib in postmenopausal women with ER/PgR+ breast cancer (Study 223). J Clin Oncol 2006; 24: 6s.
19. Viale G, Regan M, Dell'Orto B et al. Central review of ER, PgR and HER2 in BIG 1-98 evaluating letrozole vs tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Breast Cancer Res Treat 2005; 94: S13.
20. Dowsett M, Martin LA, Smith I, Johnston S. Mechanisms of resistance to aromatase inhibitors. J Steroid Biochem Mol Biol 2005; 95: 167–72.
21. Bertelli G, Garrone O, Merlano M et al. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer. Oncology 2005; 69: 471–7.
22. Seeman E. Pathogenesis of bone fragility in women and men. Lancet 2002; 359: 1841–50. jnci.oxfordjournals.org JNCI | Articles 1853
23. Winer EP, Hudis C, Burstein HJ et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor – positive breast cancer: status report 2004. J Clin Oncol 2005; 23: 619–29.
Авторы
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.